# EDGAR Filing Document

**Accession Number:** 0000019584
**File Stem:** 0000019584-26-000002
**Filing Date:** 2026-2
**Character Count:** 67577
**Document Hash:** c3f0a01d42d0869e804e984afd4c36ea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000019584-26-000002.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0000019584-26-000002

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260225

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHEMED CORP
- **CENTRAL INDEX KEY:** 0000019584
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 310791746
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-08351
- **FILM NUMBER:** 26679249

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 2600
- **STREET 2:** 255 E FIFTH ST
- **CITY:** CINCINNATI
- **STATE:** OH
- **ZIP:** 45202
- **BUSINESS PHONE:** (513)762-6690

**MAIL ADDRESS:**
- **STREET 1:** SUITE 2600
- **STREET 2:** 255 E FIFTH STREET
- **CITY:** CINCINNATI
- **STATE:** OH
- **ZIP:** 45202-4726

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ROTO-ROOTER INC
- **DATE OF NAME CHANGE:** 20030613

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEMED CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? che-20260225x8k

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):

February 25, 2026

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

      <br> <u>Delaware </u> <u> 1-8351 </u> <u> 31-0791746 </u> <br> <u>(State or other‎jurisdiction of‎incorporation)</u> <u>(Commission File Number)</u> <u>(I.R.S. Employer‎Identification‎Number)</u>

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:

(513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_] &nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] &nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12)

[_] &nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b))

[_] &nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

---

| | |
|:---|:---|
| <br>**Title of each class** | **Name of each exchange on which**<br>**registered** |
| Capital stock $1 par value <br> CHE  | NYSE  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]

Page 1 of 3

------

**Item 2.02 Results of Operations and Financial Condition**

On February 25, 2026, Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the release is furnished herewith as Exhibit 99.

**Item 9.01 Financial Statements and Exhibits**

---

| | |
|:---|:---|
| d) | Exhibit |
|  | [<u>(99) Registrant's press release dated December 31, 2025</u>](che-20260225xex99.htm) |
|  | 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL |

---

Page 2 of 3

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | CHEMED CORPORATION | CHEMED CORPORATION |
| Dated: <u>February 25, 2026</u> | By: | /s/ <u>Michael D. Witzeman</u> |
|  |  | Michael D. Witzeman |
|  |  | Executive Vice President and Chief Financial Officer |

---

Page 3 of 3

## Ex-99

![Picture 2](che-20260225xex99g001.jpg)

CONTACT: Michael D. Witzeman

(513) 762-6714

**Chemed Reports Fourth-Quarter 2025 Results** 

CINCINNATI, February 25, 2026—Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2025, versus the comparable prior-year period.

<u>Results for Quarter Ended December 31, 2025</u>

Consolidated operating results:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Revenue was $639.3 million, essentially flat with the fourth quarter of 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· GAAP Diluted Earnings-per-Share (EPS) of $5.48, a decrease of 9.0%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Adjusted Diluted EPS of $6.42, a decrease of 6.0%

VITAS segment operating results:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Net Patient Revenue of $418.8 million, an increase of 1.9%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Average Daily Census (ADC) of 22,462, an increase of 1.3%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Admissions of 17,419, an increase of 6.0%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Net Income, excluding certain discrete items, of $69.5 million, a decrease of 0.6%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Adjusted EBITDA, excluding Medicare Cap, of $91.6 million, a decrease of 1.7%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Adjusted EBITDA margin, excluding Medicare Cap, of 21.7%, a decrease of 79-basis points

Roto-Rooter segment operating results:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Revenue of $220.6 million, a decrease of 3.7%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Net Income, excluding certain discrete items, of $33.8 million, a decrease of 20.6%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Adjusted EBITDA of $47.5 million, a decline of 21.1%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Adjusted EBITDA margin of 21.5%, a decline of 477-basis points

<u>VITAS</u>

VITAS net revenue was $418.8 million in the fourth quarter of 2025, which is an increase of 1.9% when compared to the prior-year period. This revenue increase is comprised primarily of a 1.3% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.2%. Acuity mix shift negatively impacted revenue growth 143-basis

------

points in the quarter when compared to the prior-year period's revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes negatively impacted revenue growth by 20-basis points.

Total VITAS admissions increased 6.0% in the fourth quarter of 2025 compared to the fourth quarter of 2024.

In the fourth quarter of 2025, VITAS accrued $2.4 million in Medicare Cap billing limitation, essentially flat compared to the fourth quarter of 2024. There was no Medicare Cap billing limitation recorded in the fourth quarter of 2025 related to the Florida combined program.

Of VITAS' 33 Medicare provider numbers, 22 provider numbers have a projected full-year Medicare Cap cushion of 10% or greater, six provider numbers have a projected cushion between 0% and 10%, and five provider numbers have a Medicare Cap billing limitation totaling $9.5 million projected for the full-year 2026 Medicare Cap year. There is no Medicare Cap for the 2026 Cap year currently projected for the Florida combined program.

Average revenue per patient per day in the fourth quarter of 2025 was $208.01 which is 86-basis points above the prior-year period. Reimbursement for routine home care and high acuity care averaged $187.19 and $1,153.55, respectively. During the quarter, high acuity days-of-care were 2.2% of total days of care, a decline of 32-basis points when compared to the prior-year quarter.

The fourth quarter 2025 gross margin, excluding Medicare Cap, was 27.3%, a 150-basis point decline from the same period of 2024. Selling, general and administrative expenses were $23.8 million in the fourth quarter of 2025 compared to $25.6 million in the prior-year quarter.

Adjusted EBITDA, excluding Medicare Cap, totaled $91.6 million in the quarter, a decline of 1.7% when compared to the prior year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 21.7%.

<u>Roto-Rooter</u>

Roto-Rooter generated quarterly revenue of $220.6 million in the fourth quarter of 2025, a decrease of 3.7%, when compared to the prior-year quarter.

Roto-Rooter branch commercial revenue in the quarter totaled $55.2 million, an increase of 1.6% from the prior-year period. This aggregate commercial revenue change consisted of excavation increasing 10.9%, drain cleaning increasing 2.0%, plumbing flat between years, offset by a decline in water restoration of 20.0%.

Roto-Rooter branch residential revenue in the quarter totaled $155.6 million, a decrease of 3.1%, over the prior-year period. This aggregate residential revenue change consisted of plumbing increasing 6.3%, excavation essentially flat between periods, offset by water restoration decreasing 10.3% and drain cleaning declining 3.2%.

------

In the fourth quarter of 2025, revenue from independent contractors was $16.7 million which is a decline of 2.8% as compared to the same period of 2024.

Roto-Rooter's fourth quarter 2025 gross margin was 49.8%. This compares to the prior year quarter's gross margin of 51.3%. Roto-Rooter's selling, general and administrative expenses were $63.2 million in the quarter, which is an increase of 10.5% compared to the fourth quarter of 2024.

Adjusted EBITDA in the fourth quarter of 2025 totaled $47.5 million, a decrease of 21.1% when compared to the fourth quarter of 2024. The Adjusted EBITDA margin in the quarter was 21.5% which represents a 477-basis point decline from the fourth quarter of 2024.

<u>Chemed Consolidated</u>

As of December 31, 2025, Chemed had total cash and cash equivalents of $74.5 million and no current or long-term debt.

In June 2022, Chemed entered into a five-year $550 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consisted of a $100 million amortizable term loan and a $450 million revolving credit facility. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. There is approximately $404.5 million undrawn borrowing capacity under the Credit Agreement after excluding $45.5 million for Letters of Credit.

During the quarter, the Company repurchased 400,000 shares of Chemed stock for $174.6 million which equates to a cost per share of $436.39. As of December 31, 2025, there was approximately $127.3 million of remaining share repurchase authorization under its plan.

<u>Guidance for 2026</u>

VITAS 2026 revenue, prior to Medicare Cap, is estimated to increase 5.5% to 6.5% when compared to 2025. ADC is estimated to increase 3.5% to 4.0%. Full year EBITDA margin, prior to Medicare Cap is estimated to be 17.5% to 18.0%. Medicare Cap billing limitations are estimated to be $9.5 million in calendar 2026 compared to $27.2 million in calendar 2025.

Roto-Rooter is forecasted to achieve full year 2026 revenue growth of 3.0% to 3.5%. Roto-Rooter's adjusted EBITDA margin for 2026 is expected to be 22.5% to 23.0%.

Based upon the above, full-year 2026 earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $23.25 to $24.25. This compares to full-year 2025 adjusted earnings per diluted share of $21.55. The 2026 guidance assumes an effective corporate tax rate on adjusted earnings of 24.5% and a diluted share count of 13.9 million shares.

The 2026 earnings trajectory is weighted towards the second half of the year. An estimated 55% of the consolidated adjusted net income and consolidated adjusted EBITDA, prior to Medicare

------

Cap, is projected to be generated in the second half of the year. Momentum is expected to build sequentially, quarter-to-quarter throughout the year.

We believe VITAS has successfully mitigated its Florida Medicare Cap issue. As a result, in 2026, the patient mix should moderate to a more favorable balance of short and longer-stay patients. However, the financial impact of admitting a higher number of potentially longer-stay patients does not come until roughly a fiscal quarter post-admission.

Roto-Rooter's first quarter of 2025 was its strongest revenue and EBITDA margin quarter of the year. Additionally, Roto-Rooter is projected to have elevated expenses in the first half of the year in order to fund revenue growth and long-term margin improvement projects currently underway.

Management will provide more detail related to the above discussion during the conference call tomorrow morning.

<u>Conference Call</u>

As previously disclosed, Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday February 26, 2026, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, <u>Investor Relations Home \| Chemed Corporation</u> or the hosting website <u>https://edge.media-server.com/mmc/p/srzsz65g</u>**.**

Participants may also register via teleconference at:

<u>https://register-conf.media-server.com/register/BIe4160b0d86fb4a3cb11588d64e00d9e7</u>.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website.

Chemed operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed's EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed's financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company's operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed's management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed's management to estimate the resources required to meet Chemed's future financial obligations and expenditures. Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed's net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION

*Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed's operations, including Medicare Cap and Medicare reimbursement rates, Chemed's estimates of the effect of Medicare Cap on VITAS' revenues and future prospects, Chemed's expectations regarding VITAS' patient mix and Chemed's expectations regarding demand for Roter-Rooter's services.* 

*Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed's control. Chemed's actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed's Annual Report on Form 10-K for the year ended December 31, 2024 and in its Quarterly Reports filed in 2025. Any forward-looking statement made by Chemed in this press release is based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.*

                          

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** |
| (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) |
|  | Three Months Ended December 31, | Three Months Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
|  | **2025** | 2024 | **2025** | 2024 |
| Service revenues and sales | $**639337** | $639993 | $**2529978** | 2431287 |
| Cost of services provided and goods sold | **417016** | 405875 | **1706794** | 1576939 |
| Selling, general and administrative expenses (aa) | **105503** | 104251 | **417188** | 424360 |
| Depreciation | **13759** | 13263 | **54557** | 52864 |
| Amortization | **2571** | 2568 | **10284** | 10185 |
| Other operating (income)/expense | **(166)** | 158 | **2909** | 446 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total costs and expenses | **538683** | 526115 | **2191732** | 2064794 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income from operations | **100654** | 113878 | **338246** | 366493 |
| Interest expense | **(521)** | (499) | **(1750)** | (1780) |
| Other income--net (bb) | **5312** | 6744 | **19282** | 34752 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income before income taxes | **105445** | 120123 | **355778** | 399465 |
| Income taxes | **(28694)** | (29804) | **(90540)** | (97466) |
| Net income | $**76751** | $90319 | $**265238** | $301999 |
| **Earnings Per Share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income | $**5.48** | $6.08 | $**18.42** | $20.10 |
| &nbsp;&nbsp;&nbsp;&nbsp; Average number of shares outstanding | **13994** | 14853 | **14398** | 15024 |
| **Diluted Earnings Per Share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income | $**5.48** | $6.02 | $**18.34** | $19.89 |
| &nbsp;&nbsp;&nbsp;&nbsp; Average number of shares outstanding | **14010** | 14992 | **14460** | 15186 |
| (aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands): | (aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands): | (aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands): | (aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands): | (aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands): |
|  | Three Months Ended December 31, | Three Months Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
|  | **2025** | 2024 | **2025** | 2024 |
| SG&A expenses before long-term incentive compensation |  |  |  |  |
| &nbsp;&nbsp; and the impact of market value adjustments related to |  |  |  |  |
| &nbsp;&nbsp; deferred compensation plans | $**99412** | $96358 | $**401013** | $384069 |
| Market value adjustments related to deferred |  |  |  |  |
| &nbsp;&nbsp; compensation trusts | **3759** | 3539 | **10550** | 20139 |
| Long-term incentive compensation | **2332** | 4354 | **5625** | 20152 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total SG&A expenses | $**105503** | $104251 | $**417188** | $424360 |
| (bb) Other income--net comprises (in thousands): | (bb) Other income--net comprises (in thousands): | (bb) Other income--net comprises (in thousands): |  |  |
|  | Three Months Ended December 31, | Three Months Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
|  | **2025** | 2024 | **2025** | 2024 |
| Market value adjustments related to deferred |  |  |  |  |
| &nbsp;&nbsp; compensation trusts | $**3759** | $3539 | $**10550** | $20139 |
| Interest income | **1559** | 3205 | **8745** | 14610 |
| Other | **(6)** | &nbsp;&nbsp;&nbsp;&nbsp;- | **(13)** | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total other income--net | $**5312** | $6744 | $**19282** | $34752 |

---

------

---

| | | |
|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **CONSOLIDATED BALANCE SHEETS** | **CONSOLIDATED BALANCE SHEETS** | **CONSOLIDATED BALANCE SHEETS** |
| (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) |
|  | December 31, | December 31, |
|  | **2025** | 2024 |
| **Assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $**74515** | $178350 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable less allowances | **182575** | 171163 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | **7543** | 8193 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid income taxes | **11165** | 11068 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses | **26818** | 25974 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | **302616** | 394748 |
| &nbsp;&nbsp;&nbsp;&nbsp; Investments of deferred compensation plans held in trust | **140347** | 130960 |
| &nbsp;&nbsp;&nbsp;&nbsp; Properties and equipment, at cost less accumulated depreciation | **205662** | 200837 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease right of use asset | **131151** | 127323 |
| &nbsp;&nbsp;&nbsp;&nbsp; Identifiable intangible assets less accumulated amortization | **82764** | 92206 |
| &nbsp;&nbsp;&nbsp;&nbsp; Goodwill | **666999** | 666744 |
| &nbsp;&nbsp;&nbsp;&nbsp; Other assets | **8650** | 55757 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Assets | $**1538189** | $1668575 |
| **Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $**64459** | $44146 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued insurance | **62054** | 56703 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued income taxes | **2504** | 7593 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued compensation | **58329** | 92073 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-term lease liability | **40892** | 42306 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other current liabilities | **58892** | 42874 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | **287130** | 285695 |
| &nbsp;&nbsp;&nbsp;&nbsp; Deferred income taxes | **19313** | 25945 |
| &nbsp;&nbsp;&nbsp;&nbsp; Deferred compensation liabilities | **136139** | 126035 |
| &nbsp;&nbsp;&nbsp;&nbsp; Long-term lease liability | **102867** | 98538 |
| &nbsp;&nbsp;&nbsp;&nbsp; Other liabilities | **13335** | 13369 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Liabilities | **558784** | 549582 |
| **Stockholders' Equity** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Capital stock | **37595** | 37422 |
| &nbsp;&nbsp;&nbsp;&nbsp; Paid-in capital | **1592197** | 1484176 |
| &nbsp;&nbsp;&nbsp;&nbsp; Retained earnings | **2955375** | 2721832 |
| &nbsp;&nbsp;&nbsp;&nbsp; Treasury stock, at cost | **(3608117)** | (3126660) |
| &nbsp;&nbsp;&nbsp;&nbsp; Deferred compensation payable in Company stock | **2355** | 2223 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Stockholders' Equity | **979405** | 1118993 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Liabilities and Stockholders' Equity | $**1538189** | $1668575 |

---

------

---

| | | |
|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **CONSOLIDATED STATEMENTS OF CASH FLOWS** | **CONSOLIDATED STATEMENTS OF CASH FLOWS** | **CONSOLIDATED STATEMENTS OF CASH FLOWS** |
| (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) |
|  | For the Years Ended December 31, | For the Years Ended December 31, |
|  | **2025** | 2024 |
| **Cash Flows from Operating Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income | $**265238** | $301999 |
| &nbsp;&nbsp;&nbsp;&nbsp; Adjustments to reconcile net income to net cash provided |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization | **64841** | 63049 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | **32671** | 32033 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benefit for deferred income taxes | **(5944)** | (4138) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Noncash long-term incentive compensation | **4886** | 18794 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Litigation settlements | **1425** | (5750) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Noncash directors' compensation | **1123** | 1282 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of debt issuance costs | **321** | 321 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in operating assets and liabilities, excluding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amounts acquired in business combinations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Increase)/decrease in accounts receivable | **(11596)** | 10678 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in inventories | **650** | 3831 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Increase)/decrease in prepaid expenses | **(844)** | 4237 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in accounts payable and |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other current liabilities | **(5194)** | (9279) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in current income taxes | **(6217)** | 2182 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net change in lease assets and liabilities | **(806)** | (674) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease/(increase) in other assets | **36835** | (25591) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in other liabilities | **10424** | 22749 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other sources | **459** | 1774 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by operating activities | **388272** | 417497 |
| **Cash Flows from Investing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Capital expenditures | **(62795)** | (49531) |
| &nbsp;&nbsp;&nbsp;&nbsp; Proceeds from sale of fixed assets | **4568** | 3315 |
| &nbsp;&nbsp;&nbsp;&nbsp; Business combinations, net of cash acquired | **(225)** | (97400) |
| &nbsp;&nbsp;&nbsp;&nbsp; Other uses | **(888)** | (295) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used by investing activities | **(59340)** | (143911) |
| **Cash Flows from Financing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Purchases of treasury stock | **(431500)** | (361389) |
| &nbsp;&nbsp;&nbsp;&nbsp; Dividends paid | **(31695)** | (27092) |
| &nbsp;&nbsp;&nbsp;&nbsp; Proceeds from exercise of stock options | **27152** | 56517 |
| &nbsp;&nbsp;&nbsp;&nbsp; Change in cash overdrafts payable | **10970** | (15749) |
| &nbsp;&nbsp;&nbsp;&nbsp; Capital stock surrendered to pay taxes on stock-based compensation | **(8819)** | (9457) |
| &nbsp;&nbsp;&nbsp;&nbsp; Other sources/(uses) | **1125** | (2024) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used by financing activities | **(432767)** | (359194) |
| **Decrease in Cash and Cash Equivalents** | **(103835)** | (85608) |
| Cash and cash equivalents at beginning of year | **178350** | 263958 |
| Cash and cash equivalents at end of period | $**74515** | $178350 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** |
| **FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** |
| (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **2025 (a)** |  |  |  |  |
| Service revenues and sales | $418760 | $220577 | $&nbsp;&nbsp;&nbsp;&nbsp;- | $639337 |
| Cost of services provided and goods sold | 306238 | 110778 | &nbsp;&nbsp;&nbsp;&nbsp;- | 417016 |
| Selling, general and administrative expenses | 23814 | 63192 | 18497 | 105503 |
| Depreciation | 5446 | 8301 | 12 | 13759 |
| Amortization | 26 | 2545 | &nbsp;&nbsp;&nbsp;&nbsp;- | 2571 |
| Other operating income | 219 | (385) | &nbsp;&nbsp;&nbsp;&nbsp;- | (166) |
| &nbsp;&nbsp;&nbsp;&nbsp; Total costs and expenses | 335743 | 184431 | 18509 | 538683 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) from operations | 83017 | 36146 | (18509) | 100654 |
| Interest expense | (35) | (217) | (269) | (521) |
| Intercompany interest income/(expense) | 6020 | 4315 | (10335) | &nbsp;&nbsp;&nbsp;&nbsp;- |
| Other income—net | 156 | 13 | 5143 | 5312 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) before income taxes | 89158 | 40257 | (23970) | 105445 |
| Income taxes | (20169) | (8692) | 167 | (28694) |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income/(loss) | $68989 | $31565 | $(23803) | $76751 |
| 2024 (b) |  |  |  |  |
| Service revenues and sales | $411008 | $228985 | $&nbsp;&nbsp;&nbsp;&nbsp;- | $639993 |
| Cost of services provided and goods sold | 294456 | 111419 | &nbsp;&nbsp;&nbsp;&nbsp;- | 405875 |
| Selling, general and administrative expenses | 25597 | 57168 | 21486 | 104251 |
| Depreciation | 5074 | 8177 | 12 | 13263 |
| Amortization | 26 | 2542 | &nbsp;&nbsp;&nbsp;&nbsp;- | 2568 |
| Other operating expense | 18 | 140 | &nbsp;&nbsp;&nbsp;&nbsp;- | 158 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total costs and expenses | 325171 | 179446 | 21498 | 526115 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) from operations | 85837 | 49539 | (21498) | 113878 |
| Interest expense | (33) | (81) | (385) | (499) |
| Intercompany interest income/(expense) | 5114 | 3759 | (8873) | &nbsp;&nbsp;&nbsp;&nbsp;- |
| Other income—net | 90 | 5 | 6649 | 6744 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) before income taxes | 91008 | 53222 | (24107) | 120123 |
| Income taxes | (20897) | (12500) | 3593 | (29804) |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income/(loss) | $70111 | $40722 | $(20514) | $90319 |
| The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** | **CONSOLIDATING STATEMENTS OF INCOME** |
| **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** |
| (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **2025 (a)** |  |  |  |  |
| Service revenues and sales | $1630101 | $899877 | $&nbsp;&nbsp;&nbsp;&nbsp;- | $2529978 |
| Cost of services provided and goods sold | 1257704 | 449090 | &nbsp;&nbsp;&nbsp;&nbsp;- | 1706794 |
| Selling, general and administrative expenses | 100675 | 247047 | 69466 | 417188 |
| Depreciation | 21308 | 33200 | 49 | 54557 |
| Amortization | 104 | 10180 | &nbsp;&nbsp;&nbsp;&nbsp;- | 10284 |
| Other operating expense/(income) | 3375 | (466) | &nbsp;&nbsp;&nbsp;&nbsp;- | 2909 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total costs and expenses | 1383166 | 739051 | 69515 | 2191732 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) from operations | 246935 | 160826 | (69515) | 338246 |
| Interest expense | (185) | (611) | (954) | (1750) |
| Intercompany interest income/(expense) | 22455 | 16245 | (38700) | &nbsp;&nbsp;&nbsp;&nbsp;- |
| Other income—net | 327 | 70 | 18885 | 19282 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) before income taxes | 269532 | 176530 | (90284) | 355778 |
| Income taxes | (65523) | (41037) | 16020 | (90540) |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income/(loss) | $204009 | $135493 | $(74264) | $265238 |
| 2024 (b) |  |  |  |  |
| Service revenues and sales | $1530978 | $900309 | $&nbsp;&nbsp;&nbsp;&nbsp;- | $2431287 |
| Cost of services provided and goods sold | 1146803 | 430136 | &nbsp;&nbsp;&nbsp;&nbsp;- | 1576939 |
| Selling, general and administrative expenses | 99564 | 232852 | 91944 | 424360 |
| Depreciation | 20362 | 32452 | 50 | 52864 |
| Amortization | 105 | 10080 | &nbsp;&nbsp;&nbsp;&nbsp;- | 10185 |
| Other operating expense | 178 | 268 | &nbsp;&nbsp;&nbsp;&nbsp;- | 446 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total costs and expenses | 1267012 | 705788 | 91994 | 2064794 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) from operations | 263966 | 194521 | (91994) | 366493 |
| Interest expense | (171) | (431) | (1178) | (1780) |
| Intercompany interest income/(expense) | 20211 | 14397 | (34608) | &nbsp;&nbsp;&nbsp;&nbsp;- |
| Other income—net | 227 | 69 | 34456 | 34752 |
| &nbsp;&nbsp;&nbsp;&nbsp; Income/(loss) before income taxes | 284233 | 208556 | (93324) | 399465 |
| Income taxes | (67414) | (48510) | 18458 | (97466) |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income/(loss) | $216819 | $160046 | $(74866) | $301999 |
| The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** |
| **FOR THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024** |
| (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **2025** |  |  |  |  |
| Net income/(loss) | $68989 | $31565 | $(23803) | $76751 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest expense | 35 | 217 | 269 | 521 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income taxes | 20169 | 8692 | (167) | 28694 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation | 5446 | 8301 | 12 | 13759 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization | 26 | 2545 | &nbsp;&nbsp;&nbsp;&nbsp;- | 2571 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBITDA | 94665 | 51320 | (23689) | 122296 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intercompany interest expense/(income) | (6020) | (4315) | 10335 | &nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest income | (156) | (19) | (1384) | (1559) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 8297 | 8297 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 2332 | 2332 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Legal settlements | 221 | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 221 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | 500 | 530 | 25 | 1055 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjusted EBITDA | $89210 | $47516 | $(4084) | $132642 |
| 2024 |  |  |  |  |
| Net income/(loss) | $70111 | $40722 | $(20514) | $90319 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest expense | 33 | 81 | 385 | 499 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income taxes | 20897 | 12500 | (3593) | 29804 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation | 5074 | 8177 | 12 | 13263 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization | 26 | 2542 | &nbsp;&nbsp;&nbsp;&nbsp;- | 2568 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBITDA | 96141 | 64022 | (23710) | 136453 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intercompany interest expense/(income) | (5114) | (3759) | 8873 | &nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest income | (89) | (5) | (3111) | (3205) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 8100 | 8100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 4354 | 4354 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition expense | (203) | (3) | &nbsp;&nbsp;&nbsp;&nbsp;- | (206) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjusted EBITDA | $90735 | $60255 | $(5494) | $145496 |
| The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** | **CONSOLIDATING SUMMARIES OF EBITDA** |
| **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024** |
| (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) | (in thousands)(unaudited) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **2025** |  |  |  |  |
| Net income/(loss) | $204009 | $135493 | $(74264) | $265238 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest expense | 185 | 611 | 954 | 1750 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income taxes | 65523 | 41037 | (16020) | 90540 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation | 21308 | 33200 | 49 | 54557 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization | 104 | 10180 | &nbsp;&nbsp;&nbsp;&nbsp;- | 10284 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBITDA | 291129 | 220521 | (89281) | 422369 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intercompany interest expense/(income) | (22455) | (16245) | 38700 | &nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest income | (334) | (77) | (8335) | (8746) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 32671 | 32671 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 5625 | 5625 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Legal settlements | 3071 | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 3071 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | 500 | 530 | 2690 | 3720 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjusted EBITDA | $271911 | $204729 | $(17930) | $458710 |
| 2024 |  |  |  |  |
| Net income/(loss) | $216819 | $160046 | $(74866) | $301999 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest expense | 171 | 431 | 1178 | 1780 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income taxes | 67414 | 48510 | (18458) | 97466 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation | 20362 | 32452 | 50 | 52864 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization | 105 | 10080 | &nbsp;&nbsp;&nbsp;&nbsp;- | 10185 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBITDA | 304871 | 251519 | (92096) | 464294 |
| Add/(deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intercompany interest expense/(income) | (20211) | (14397) | 34608 | &nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest income | (224) | (69) | (14317) | (14610) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 32033 | 32033 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 20152 | 20152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition expense | 1099 | 34 | &nbsp;&nbsp;&nbsp;&nbsp;- | 1133 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjusted EBITDA | $285535 | $237087 | $(19620) | $503002 |
| The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **RECONCILIATION OF ADJUSTED NET INCOME** | **RECONCILIATION OF ADJUSTED NET INCOME** | **RECONCILIATION OF ADJUSTED NET INCOME** | **RECONCILIATION OF ADJUSTED NET INCOME** | **RECONCILIATION OF ADJUSTED NET INCOME** |
| (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) | (in thousands, except per share data)(unaudited) |
|  | Three Months Ended December 31, | Three Months Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
|  | **2025** | 2024 | **2025** | 2024 |
| Net income as reported | $**76751** | $90319 | $**265238** | $301999 |
| Add/(deduct) pre-tax cost of: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | **8297** | 8100 | **32671** | 32033 |
| &nbsp;&nbsp;&nbsp;&nbsp; Amortization of reacquired franchise rights | **2352** | 2352 | **9408** | 9408 |
| &nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | **2332** | 4354 | **5625** | 20152 |
| &nbsp;&nbsp;&nbsp;&nbsp; Legal settlements | **221** | &nbsp;&nbsp;&nbsp;&nbsp;- | **3071** | &nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition expense | **-** | (206) | **-** | 1133 |
| &nbsp;&nbsp;&nbsp;&nbsp; Other | **1055** | &nbsp;&nbsp;&nbsp;&nbsp;- | **3720** | &nbsp;&nbsp;&nbsp;&nbsp;- |
| Add/(deduct) tax impacts: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Tax impact of the above pre-tax adjustments (1) | **(2337)** | (2333) | **(8849)** | (9095) |
| &nbsp;&nbsp;&nbsp;&nbsp; Excess tax benefits on stock compensation | **1209** | (133) | **696** | (4442) |
| Adjusted net income | $**89880** | $102453 | $**311580** | $351188 |
| Diluted Earnings Per Share As Reported |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income | $**5.48** | $6.02 | $**18.34** | $19.89 |
| &nbsp;&nbsp;&nbsp;&nbsp; Average number of shares outstanding | **14010** | 14992 | **14460** | 15186 |
| Adjusted Diluted Earnings Per Share |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Adjusted net income | $**6.42** | $6.83 | $**21.55** | $23.13 |
| &nbsp;&nbsp;&nbsp;&nbsp; Average number of shares outstanding | **14010** | 14992 | **14460** | 15186 |
| (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. | (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. | (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. | (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. | (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |
| The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. | The "Footnotes to Financial Statements" are integral parts of this financial information. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **OPERATING STATISTICS FOR VITAS SEGMENT** | **OPERATING STATISTICS FOR VITAS SEGMENT** | **OPERATING STATISTICS FOR VITAS SEGMENT** | **OPERATING STATISTICS FOR VITAS SEGMENT** | **OPERATING STATISTICS FOR VITAS SEGMENT** |
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
|  | Three Months Ended December 31, | Three Months Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
| OPERATING STATISTICS | **2025** | 2024 | **2025** | 2024 |
| &nbsp;&nbsp; Net revenue ($000) (c) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Homecare | $**372480** | $358507 | $**1444494** | $1326488 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inpatient | **32903** | 31307 | **133048** | 120604 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuous care | **18438** | 25451 | **86661** | 99746 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | **6029** | 5556 | **22926** | 19455 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subtotal | $**429850** | $420821 | $**1687129** | $1566293 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Room and board, net | **(4285)** | (3867) | **(15562)** | (13304) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contractual allowances | **(4430)** | (3521) | **(14305)** | (13597) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicare cap allowance | **(2375)** | (2425) | **(27161)** | (8414) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net Revenue | $**418760** | $411008 | $**1630101** | $1530978 |
| &nbsp;&nbsp; Net revenue as a percent of total before Medicare cap allowance |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Homecare | **86.7%** | 85.2% | **85.6%** | 84.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inpatient | **7.7** | 7.4 | **7.9** | 7.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuous care | **4.3** | 6.0 | **5.1** | 6.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | **1.3** | 1.4 | **1.4** | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subtotal | **100.0** | 100.0 | **100.0** | 100.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Room and board, net | **(0.9)** | (0.9) | **(0.9)** | (0.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contractual allowances | **(1.0)** | (0.8) | **(0.9)** | (0.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicare cap allowance | **(0.6)** | (0.6) | **(1.6)** | (0.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net Revenue | **97.5%** | 97.7% | **96.6%** | 97.8% |
| &nbsp;&nbsp; Days of care |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Homecare | **1705085** | 1656206 | **6685968** | 6277961 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nursing home | **305331** | 322713 | **1228789** | 1230726 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respite | **11602** | 11155 | **45221** | 37961 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subtotal routine homecare and respite | **2022018** | 1990074 | **7959978** | 7546648 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inpatient | **27444** | 27235 | **113891** | 106299 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuous care | **17063** | 23189 | **79639** | 95524 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total | **2066525** | 2040498 | **8153508** | 7748471 |
| &nbsp;&nbsp; Number of days in relevant time period | **92** | 92 | **365** | 366 |
| &nbsp;&nbsp; Average daily census ("ADC") (days) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Homecare | **18533** | 18002 | **18318** | 17153 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nursing home | **3319** | 3508 | **3367** | 3363 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respite | **126** | 121 | **123** | 104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subtotal routine homecare and respite | **21978** | 21631 | **21808** | 20620 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inpatient | **298** | 296 | **312** | 290 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuous care | **186** | 252 | **218** | 261 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total | **22462** | 22179 | **22338** | 21171 |
| &nbsp;&nbsp; Total Admissions | **17419** | 16427 | **70817** | 67447 |
| &nbsp;&nbsp; Total Discharges | **17599** | 16333 | **70530** | 64618 |
| &nbsp;&nbsp; Average length of stay (days) | **115.1** | 105.5 | **120.2** | 103.0 |
| &nbsp;&nbsp; Median length of stay (days) | **17.0** | 18.0 | **18.0** | 17.0 |
| &nbsp;&nbsp; ADC by major diagnosis |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cerebro | **44.3%** | 44.2% | **44.6%** | 44.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurological | **11.4** | 12.9 | **11.7** | 13.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer | **10.0** | 9.9 | **9.8** | 10.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardio | **16.0** | 16.2 | **16.0** | 16.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory | **7.6** | 6.9 | **7.4** | 7.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | **10.7** | 9.9 | **10.5** | 9.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| &nbsp;&nbsp; Admissions by major diagnosis |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cerebro | **27.3%** | 28.0% | **27.4%** | 27.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurological | **6.8** | 7.0 | **6.9** | 7.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer | **26.4** | 25.9 | **26.0** | 25.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardio | **14.6** | 15.3 | **14.7** | 15.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory | **10.8** | 9.8 | **10.9** | 9.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | **14.1** | 14.0 | **14.1** | 13.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| Estimated uncollectible accounts as a percent of revenues | **1.1%** | 0.9% | **1.0%** | 0.9% |
| Accounts receivable -- |  |  |  |  |
| Days of revenue outstanding-excluding unapplied Medicare payments | **38.7** | 40.0 | **n.a.** | n.a. |
| Days of revenue outstanding-including unapplied Medicare payments | **28.9** | 28.5 | **n.a.** | n.a. |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** | **CHEMED CORPORATION AND SUBSIDIARY COMPANIES** |
| **FOOTNOTES TO FINANCIAL STATEMENTS** | **FOOTNOTES TO FINANCIAL STATEMENTS** | **FOOTNOTES TO FINANCIAL STATEMENTS** | **FOOTNOTES TO FINANCIAL STATEMENTS** | **FOOTNOTES TO FINANCIAL STATEMENTS** | **FOOTNOTES TO FINANCIAL STATEMENTS** |
| **FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025 AND 2024** | **FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025 AND 2024** |
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
| (a) | Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations |
|  | (in thousands): |  |  |  |  |
|  |  | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** |
|  |  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | $&nbsp;&nbsp;&nbsp;&nbsp;- | $&nbsp;&nbsp;&nbsp;&nbsp;- | $(8297) | $(8297) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization of reacquired franchise agreements | &nbsp;&nbsp;&nbsp;&nbsp;- | (2352) | &nbsp;&nbsp;&nbsp;&nbsp;- | (2352) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (2332) | (2332) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Legal settlements | (221) | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (221) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Other | (500) | (530) | (25) | (1055) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pretax impact on earnings | (721) | (2882) | (10654) | (14257) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Excess tax benefits on stock compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (1209) | (1209) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Income tax benefit on the above | 170 | 679 | 1488 | 2337 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After-tax impact on earnings | $(551) | $(2203) | $(10375) | $(13129) |
|  |  | **For the Years Ended December 31, 2025** | **For the Years Ended December 31, 2025** | **For the Years Ended December 31, 2025** | **For the Years Ended December 31, 2025** |
|  |  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | $&nbsp;&nbsp;&nbsp;&nbsp;- | $&nbsp;&nbsp;&nbsp;&nbsp;- | $(32671) | $(32671) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization of reacquired franchise agreements | &nbsp;&nbsp;&nbsp;&nbsp;- | (9408) | &nbsp;&nbsp;&nbsp;&nbsp;- | (9408) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (5625) | (5625) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Legal settlements | (3071) | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (3071) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Other | (500) | (530) | (2690) | (3720) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pretax impact on earnings | (3571) | (9938) | (40986) | (54495) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Excess tax benefits on stock compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (696) | (696) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Income tax benefit on the above | 868 | 2316 | 5665 | 8849 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After-tax impact on earnings | $(2703) | $(7622) | $(36017) | $(46342) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| (b) | Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations | Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations |
|  | (in thousands): |  |  |  |  |
|  |  | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
|  |  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | $&nbsp;&nbsp;&nbsp;&nbsp;- | $&nbsp;&nbsp;&nbsp;&nbsp;- | $(8100) | $(8100) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (4354) | (4354) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization of reacquired franchise agreements | &nbsp;&nbsp;&nbsp;&nbsp;- | (2352) | &nbsp;&nbsp;&nbsp;&nbsp;- | (2352) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Acquisition expense | 203 | 3 | &nbsp;&nbsp;&nbsp;&nbsp;- | 206 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pretax impact on earnings | 203 | (2349) | (12454) | (14600) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Excess tax benefits on stock compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 133 | 133 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Income tax benefit on the above | (50) | 547 | 1836 | 2333 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After-tax impact on earnings | $153 | $(1802) | $(10485) | $(12134) |
|  |  | **For the Years Ended December 31, 2024** | **For the Years Ended December 31, 2024** | **For the Years Ended December 31, 2024** | **For the Years Ended December 31, 2024** |
|  |  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Stock option expense | $&nbsp;&nbsp;&nbsp;&nbsp;- | $&nbsp;&nbsp;&nbsp;&nbsp;- | $(32033) | $(32033) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Long-term incentive compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | (20152) | (20152) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization of reacquired franchise agreements | &nbsp;&nbsp;&nbsp;&nbsp;- | (9408) | &nbsp;&nbsp;&nbsp;&nbsp;- | (9408) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Acquisition expense | (1099) | (34) | &nbsp;&nbsp;&nbsp;&nbsp;- | (1133) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pretax impact on earnings | (1099) | (9442) | (52185) | (62726) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Excess tax benefits on stock compensation | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;- | 4442 | 4442 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Income tax benefit on the above | 267 | 2200 | 6628 | 9095 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After-tax impact on earnings | $(832) | $(7242) | $(41115) | $(49189) |

---

------

(c) VITAS has 12 large (greater than 450 ADC), 23 medium (greater than 200 but less than 450 ADC) and 24 small (less than 200 ADC) hospice programs. Of Vitas' 33 Medicare provider numbers, for the current cap year, 22 provider numbers have a Medicare cap cushion of greater than 10%, six provider numbers have a Medicare cap cushion between 0% and 10%, and five provider numbers have a Medicare cap liability.

------